Clinical Immunology

The Biology and Genetics of APDS1

At a Glance

APDS1 is caused by a gain-of-function change in the PIK3CD gene, which keeps immune signaling overactive and disrupts B- and T-cell development. Genetic sequencing is central to diagnosis; functional tests may support, but cannot alone confirm, an uncertain variant.

To understand APDS1, it helps to think of your immune system as a high-performance engine. In a healthy body, this engine has a precisely tuned gas pedal that tells immune cells when to grow and fight. In APDS1, a genetic change has caused that gas pedal to become stuck in the “down” position. This state of constant “overdrive” paradoxically makes the immune system less effective at fighting real threats while causing it to grow out of control in other ways ^[1]^[2].

The Genetic “Gas Pedal”: PIK3CD

The root of APDS1 is a mutation in the PIK3CD gene. This gene provides the instructions for a protein called p110δ (p110-delta), which is a key part of the signaling pathway that tells white blood cells to activate ^[1].

Gain-of-Function: The mutation in APDS1 is called a gain-of-function mutation. This doesn’t mean the body has gained a “good” function; rather, it means the protein is “hyperactive”—it is doing its job too much ^[3]^[4].
The Chain Reaction: This hyperactive protein triggers a cascade of signals inside the cell, specifically increasing levels of a molecule called PIP3. This leads to the over-activation of other proteins, most notably AKT and mTOR/S6, which act as the engine’s main drive shaft ^[2]^[5].
Cell Confusion: Because the signal is always “on,” normal lymphocyte development and differentiation are disrupted. Depending on the cell subset, immune cells (especially B cells and T cells) can become “exhausted” or prematurely aged. They are often so busy growing and dividing that they fail to mature into the specialized cells needed to create long-term immunity ^[6]^[7]^[8].

Interpreting the Diagnosis: Beyond the Genetic Code

Most patients are diagnosed through genetic sequencing, which reads the PIK3CD gene to look for known pathogenic mutations. However, sometimes the test finds a Variant of Uncertain Significance (VUS)—a change in the gene that hasn’t been seen enough times for scientists to be sure it causes the disease ^[9]^[10].

When a VUS is found, doctors may use functional assays as specialist adjuncts to clinical interpretation:

Phospho-Flow Cytometry: This specialized blood test measures the “spark” in the engine. It looks specifically at the phosphorylation (a chemical “on” switch) of the AKT and S6 proteins ^[11]^[12].
Basal vs. Stimulated Activity: In APDS1, these proteins often show high activity even when the cell is at rest (basal activity).
The “Inhibitor Test”: Scientists may add a drug that specifically blocks the p110δ protein to the blood sample to see if the “overdrive” signaling drops. While these functional results may support a diagnosis when interpreted by an expert, they depend heavily on cell type and assay validation, and they do not independently confirm that a VUS causes APDS1 ^[13]^[14].

APDS1 vs. APDS2 vs. CVID

Because many immune disorders cause frequent infections, APDS1 overlaps clinically with other conditions. Diagnosis requires clinical, immunologic, genetic, and sometimes functional assessment by a specialist. The following are general tendencies, as overlap is substantial:

Feature	APDS1	APDS2	CVID
Genetic Cause	PIK3CD gene mutation ^[1]	PIK3R1 gene mutation ^[15]	Heterogeneous / unknown ^[9]
Biological Mechanism	Hyperactive “gas pedal” protein ^[3]	Missing “brake” on the gas pedal ^[15]	Often disturbed B-cell signaling ^[10]
General Tendencies	Primarily immune symptoms and frequent bronchiectasis ^[4]	Similar immune findings, but growth or short stature may be more frequent ^[16]^[17]	Wide overlap clinically, but may show disturbed induced signaling rather than high basal activity ^[18]
Pathology	Swollen lymph nodes are very common ^[19]	Swollen lymph nodes are very common ^[20]	Swollen nodes occur, but vary widely ^[9]

Completeness Checklist for Your Records

When reviewing your diagnostic reports, ensure the following details are present. If they are missing, it is a good starting point for a conversation with your immunologist.

Genetic Report Checklist:

[ ] Gene Name: Clearly identified as PIK3CD.
[ ] Variant Notation: The exact “name” of the mutation (e.g., c.3061G>A or p.Glu1021Lys) ^[8].
[ ] Zygosity: Usually “heterozygous,” meaning one copy of the gene is affected ^[3].
[ ] Classification: Is it labeled “Pathogenic,” “Likely Pathogenic,” or “VUS”? ^[9]

Immunology & Pathology Checklist:

[ ] Immunoglobulin Levels: Measurements of IgG, IgA, and IgM (IgM is often high in APDS) ^[21].
[ ] Lymphocyte Subsets: A breakdown of B-cell and T-cell types (often shows low “naïve” cells and high “transitional” cells) ^[22]^[23].
[ ] Biopsy Details (if applicable): If a lymph node was sampled, note that a label of “reactive” must be interpreted in clinical context; the adequacy of the biopsy, immunostains, and testing for the EBV virus are chosen for the individual case and do not automatically exclude malignancy forever ^[24]^[25].

Common questions in this guide

What genetic change causes APDS1?

APDS1 is caused by a gain-of-function change in the PIK3CD gene. This makes the p110δ part of an immune signaling pathway too active, which can disrupt the development and maturation of B cells and T cells.

How is APDS1 diagnosed?

Diagnosis usually starts with genetic sequencing of PIK3CD and is interpreted alongside the person’s infection history, immune testing, and clinical findings. If the result is uncertain, a specialist may use functional tests such as phospho-flow cytometry, but these tests do not independently prove that a variant causes APDS1.

What does a VUS in PIK3CD mean for an APDS1 diagnosis?

A variant of uncertain significance, or VUS, is a gene change for which there is not yet enough evidence to know whether it causes APDS1. Testing how active the AKT and S6 proteins are may support the overall assessment, but the result must be interpreted by a specialist and cannot confirm the VUS on its own.

How are APDS1, APDS2, and CVID different?

APDS1 is linked to a PIK3CD mutation, while APDS2 is linked to a PIK3R1 mutation. CVID has varied or sometimes unknown genetic causes, and its immune signaling pattern may differ; because symptoms overlap, specialists use clinical, immune, genetic, and sometimes functional findings to tell them apart.

Which details should I check on an APDS1 genetic report?

The report should identify PIK3CD, provide the exact variant notation, state the zygosity, and classify the variant as pathogenic, likely pathogenic, or a VUS. Keeping the full sequencing report—not only a summary—can help your care team review the result accurately.

Can a reactive lymph node biopsy rule out lymphoma in APDS1?

A report describing a lymph node as reactive must be interpreted with the clinical picture, the quality of the sample, immunostain results, and any testing for EBV. It does not automatically rule out lymphoma permanently, so your treating team should explain what the biopsy does and does not show.

Does a high IgM level suggest APDS1?

High IgM can occur in APDS1, so clinicians often review IgG, IgA, and IgM together with B-cell and T-cell subsets. This pattern is not enough by itself to establish APDS1 and must be considered with symptoms, genetic findings, and other immune tests.

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Activated PI3K-delta syndrome 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Curated prompts to bring to your next appointment.

1.Does the genetic report identify a 'gain-of-function' mutation in the PIK3CD gene, and what is the specific variant (e.g., E1021K)?
2.If the genetic result is a 'Variant of Uncertain Significance' (VUS), can we order a phospho-AKT/S6 flow cytometry test to see if it may support a diagnosis?
3.How does my/my child's clinical picture and B-cell signaling compare to what you would see in a typical case of CVID?
4.Does the pathology from the lymph node biopsy show signs of 'reactive' growth or something more concerning, like lymphoma?
5.Have we ruled out APDS2 by checking the PIK3R1 gene?

References (25)

1
Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1.
Dornan GL, Siempelkamp BD, Jenkins ML, et al.
Proceedings of the National Academy of Sciences of the United States of America 2017; (114(8)):1982-1987 doi:10.1073/pnas.1617244114.
PMID: 28167755
2
Phosphoinositide 3-kinase δ activity in patients with systemic lupus erythematosus.
Mirfazeli ES, Kharkar S, Tsang-A-Sjoe MWP, et al.
Frontiers in immunology 2026; (17()):1745692 doi:10.3389/fimmu.2026.1745692.
PMID: 41782874
3
Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.
IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ
Immunotherapy advances 2024; (4(1)):ltae009 doi:10.1093/immadv/ltae009.
PMID: 39679264
4
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maccari ME, Wolkewitz M, Schwab C, et al.
The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.
PMID: 37390899
5
Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
Rao VK, Webster S, Dalm VASH, et al.
Blood 2017; (130(21)):2307-2316 doi:10.1182/blood-2017-08-801191.
PMID: 28972011
6
Activated PIK3CD drives innate B cell expansion yet limits B cell-intrinsic immune responses.
Wray-Dutra MN, Al Qureshah F, Metzler G, et al.
The Journal of experimental medicine 2018; (215(10)):2485-2496 doi:10.1084/jem.20180617.
PMID: 30194267
7
Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
Edwards ESJ, Bier J, Cole TS, et al.
The Journal of allergy and clinical immunology 2019; (143(1)):276-291.e6 doi:10.1016/j.jaci.2018.04.030.
PMID: 29800648
8
Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8+ T Cell Survival, Differentiation, and Function.
Cannons JL, Preite S, Kapnick SM, et al.
Frontiers in immunology 2018; (9()):1758 doi:10.3389/fimmu.2018.01758.
PMID: 30116245
9
A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects.
Bildik HN, Esenboga S, Halaclı SO, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2024; (35(9)):e14245 doi:10.1111/pai.14245.
PMID: 39312287
10
Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Del Pino-Molina L, Torres Canizales JM, Rodríguez-Pena R, López-Granados E
Cytometry. Part B, Clinical cytometry 2021; (100(4)):460-466 doi:10.1002/cyto.b.21956.
PMID: 32961022
11
Technical challenges of intracellular flow cytometry-based assays as a functional complement to diagnosis of signaling defects of inborn errors of immunity: PI3K pathway as a case of study.
Del Pino Molina L, Reche Yebra K, Soto Serrano Y, et al.
Frontiers in immunology 2024; (15()):1476218 doi:10.3389/fimmu.2024.1476218.
PMID: 39620215
12
Phenotypic characterization of patients with activated PI3Kδ syndrome 1 presenting with features of systemic lupus erythematosus.
Wang Y, Yang Q, Chen X, et al.
Genes & diseases 2021; (8(6)):907-917 doi:10.1016/j.gendis.2020.04.012.
PMID: 34522717
13
Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T, Okada S, Tsumura M, et al.
Frontiers in immunology 2018; (9()):568 doi:10.3389/fimmu.2018.00568.
PMID: 29675019
14
Germline-activating mutations in PIK3CD compromise B cell development and function.
Avery DT, Kane A, Nguyen T, et al.
The Journal of experimental medicine 2018; (215(8)):2073-2095 doi:10.1084/jem.20180010.
PMID: 30018075
15
Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
Nguyen T, Lau A, Bier J, et al.
The Journal of experimental medicine 2023; (220(6)) doi:10.1084/jem.20221020.
PMID: 36943234
16
Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
Olbrich P, Lorenz M, Cura Daball P, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2016; (27(6)):640-4 doi:10.1111/pai.12585.
PMID: 27116393
17
Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort.
Oh J, Garabedian E, Fuleihan R, Cunningham-Rundles C
The journal of allergy and clinical immunology. In practice 2021; (9(11)):4095-4102 doi:10.1016/j.jaip.2021.07.044.
PMID: 34352450
18
Dysregulated PI3K Signaling in B Cells of CVID Patients.
Harder I, Münchhalfen M, Andrieux G, et al.
Cells 2022; (11(3)) doi:10.3390/cells11030464.
PMID: 35159274
19
Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME, Abolhassani H, Aghamohammadi A, et al.
Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.
PMID: 29599784
20
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E, Neven B, Bruneau J, et al.
The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.
PMID: 27221134
21
Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
Jamee M, Moniri S, Zaki-Dizaji M, et al.
Clinical reviews in allergy & immunology 2020; (59(3)):323-333 doi:10.1007/s12016-019-08738-9.
PMID: 31111319
22
Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.
Bloomfield M, Klocperk A, Zachova R, et al.
Frontiers in pediatrics 2021; (9()):697706 doi:10.3389/fped.2021.697706.
PMID: 34350147
23
Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
Wang Y, Wang W, Liu L, et al.
Journal of clinical immunology 2018; (38(8)):854-863 doi:10.1007/s10875-018-0568-x.
PMID: 30499059
24
Atypical lymphoproliferations associated with germline genetic variants: a report of the 2024 EA4HP/SH lymphoma workshop.
van den Brand M, Rásó-Barnett L, Gasljevic G, et al.
Virchows Archiv : an international journal of pathology 2025; (487(2)):275-286 doi:10.1007/s00428-025-04189-0.
PMID: 40748381
25
Case Report: Recurrent pulmonary infections with neck masses: a diagnostic challenge and literature review.
Zhao L, Zhao J, Lu Y
Frontiers in medicine 2026; (13()):1807946 doi:10.3389/fmed.2026.1807946.
PMID: 42040580

This page explains APDS1 biology and testing for informational purposes only and does not constitute medical advice. A clinical immunologist, geneticist, and pathologist should interpret your genetic, immune, and biopsy results.

Guide Contents